IDEXX Laboratories, Inc. vs Uber Technologies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $586.65 (market cap $46.93B), while Uber Technologies Inc trades at $78.29 (market cap $159.38B). The key difference: Uber Technologies Inc is far larger — about 3.4× IDEXX Laboratories, Inc.'s market cap, and Uber Technologies Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | UBER | |
|---|---|---|
Market Cap | $46.93B | $159.38B |
Sector | Health | Industrials |
52-Week High | $766.68 | $100.10 |
52-Week Low | $526.44 | $65.94 |
Enterprise Value | $47.83B | $168.72B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $586.67, down 0.56% on the day, with strong technical momentum showing bullish moving averages and key resistance at $590. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 8.4% and full-year guidance raised to $14.69-14.94. Revenue growth accelerated to 10% year-over-year, supported by 9% organic growth in companion animal diagnostics. Net income margin expanded to 25.03% with exceptional ROE of 74.21%, though valuation multiples remain elevated at P/E 41.23.
Outlook remains positive with analyst consensus at 56.5% buy ratings, though premium valuation and competitive pressures present risks. The stock's technical setup suggests potential breakout above $590 resistance could target $609-618 levels, while support at $578-570 provides downside protection. Continued execution on international expansion and diagnostic adoption supports growth trajectory.
Uber (UBER) trades at $78.54, up 4.69% today, reflecting strong bullish momentum. The stock shows robust fundamentals with revenue growth from $44.0B in 2024 to $52.0B in 2025 and a net income margin of 19.32%. Technical indicators are bullish, with the price above key support levels and moving averages signaling upward trend. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Spain and Germany, though cost management is evident through HR layoffs and AI spending caps.
The outlook for Uber is positive, driven by revenue expansion and profitability improvements, but risks include intense competition and regulatory scrutiny. Analyst consensus is strongly bullish with a $102.88 price target, suggesting significant upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →